OCIN 2025 Highlights | EverBridge Group Shines in Shanghai with Comprehensive Neuroscience Solutions

From May 16 to 18, 2025, the Oriental Conference on Cerebral Vascular Diseases (OCIN 2025) was grandly held and successfully concluded in Shanghai. EverBridge Group's Neuroscience Business Unit made a remarkable appearance at the conference, showcasing its full product portfolio and solutions, demonstrating professional expertise and innovative spirit in the field of neurological therapy.

This prestigious event brought together numerous domestic and international experts and scholars in cerebrovascular diseases, serving as an important platform for industry exchange and cutting-edge technology exhibition. During the conference, renowned neurointervention experts and peers from around the world gathered at the EverBridge Groupbooth, engaging in in-depth and enthusiastic discussions with the company's representatives.

[Aneurysm Intervention Symposium - "Optimal Solutions for Aneurysms"]

On May 17, at the "Optimal Solutions for Aneurysms" symposium, experts and peers freely exchanged views, conducting comprehensive discussions on the latest technologies and hot topics in aneurysm intervention. From diverse perspectives and through surgical video presentations, they shared their research achievements and clinical insights, exploring ways to improve surgical success rates and reduce complication rates. This open and inclusive academic atmosphere injected fresh vitality into the development of neurointerventional diagnosis and treatment. The symposium not only provided an excellent platform for industry peers to learn and exchange ideas but also fostered collaboration across the field, collectively advancing the standards of cerebrovascular disease treatment and delivering higher-quality, more efficient medical services to patients.

Moving forward, EverBridge Group's Neuroscience Business Unit will continue to uphold its innovation-driven development philosophy, further increasing R&D investment and strengthening collaborations with domestic and international research institutions. The company is committed to providing superior and more advanced solutions for the neurointerventional field. In an era of rapidly evolving neurointerventional technologies,EverBridge Group will keep pace with the times, actively exploring new treatment methods and approaches, and contributing to tackling the global challenge of cerebrovascular diseases.